Predicting the incidence of antipsychotic-induced movement disorders in long-stay patients: A prospective study

Epidemiology and Psychiatric Sciences

Volumn 22, Issue 4, 2013, Pages 375-379

  Bakker, P R ^a,b   De Groot, I W ^c   Van Os, J ^b,d   Van Harten, P N ^a,b  

^a Medisch Centrum   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Dimence Mental Health Care Expertise Centre for Bipolar Disorders   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

adverse effects; antipsychotics; incidence; movement disorders; Prospective study; risk factors

Indexed keywords

NEUROLEPTIC AGENT;

AKATHISIA; CHRONIC PATIENT; CLINICAL TRIAL; DYSTONIA; HUMAN; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; MOTOR DYSFUNCTION; PARKINSONISM; TARDIVE DYSKINESIA; ADULT; AGE; BRAIN TUMOR; FOLLOW UP; PROSPECTIVE STUDY;

ANTIPSYCHOTIC AGENTS; HUMANS; INCIDENCE; MOVEMENT DISORDERS; PROSPECTIVE STUDIES;

EID: 84897010624     PISSN: 20457960     EISSN: 20457979     Source Type: Journal    
DOI: 10.1017/S204579601300019X     Document Type: Letter

References (17)

1. Altman DG (1999). Practical Statistics for Medical Research. Chapman & Hall/CRC: Boca Raton, FL.
2. Bakker PR, de Groot IW, van Os J, van Harten PN (2011). Long-stay psychiatric patients: a prospective study revealing persistent antipsychotic-induced movement disorder. PLoS ONE 6, e25588.
3. Casey DE (2006). Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectrums 11 (Suppl. 7), 25-31. (Pubitemid 44141226)
4. Cleves MA (2008). An Introduction to Survival Analysis Using Stata, 2nd edn. Stata Press: College Station, TX.
5. Factor SA, Lang AE, Weiner WJ (2005). Drug Induced Movement Disorders, 2nd edn. Blackwell Futura: Malden, MA.
6. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276. (Pubitemid 18039085)
7. Kohler U, Kreuter F (2009). Data Analysis Using Stata, 2nd edn. Stata Press: College Station, TX.
8. Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, van Harten PN, Snieder H (2012). Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients. Psychopharmacology 219, 727-736.
9. Lambert M, Conus P, Eide P, Mass R, Karow A, Moritz S, Golks D, Naber D (2004). Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. European Psychiatry 19, 415-422. (Pubitemid 39422495)
10. Owens DGC (1999). A Guide to the Extrapyramidal Side-Effects of Antipsychotic Drugs. Cambridge University Press: New York, NY.
11. Rabe-Hesketh S, Skrondal A (2008). Multilevel and Longitudinal Modelling Using Stata, 2nd edn. Stata Press: College Station, TX.
12. Robinson DG, Woerner MG, Alvir JM, Bilder RM, Hinrichsen GA, Lieberman JA (2002). Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophrenia Research 57, 209-219. (Pubitemid 35240023)
13. Schooler NR, Kane JM (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 39, 486-487. (Pubitemid 12152819)
14. StataCorp (2009). Stata: Release 11. Statistical Software. StataCorp LP: College Station, TX.
15. Steyerberg EW (2009). Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. Springer: New York.
16. Szklo M, Nieto FJ (2007). Epidemiology: Beyond the Basics, 2nd edn. Jones and Bartlett Publishers: Sudbury, MA.
17. Tenback DE, van Harten PN, van Os J (2009). Nontherapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Movement Disorders 24, 2309-2315.